TRT unboxing videos: what the hype gets wrong about testosterone therapy

What did @kmartfit actually say?

The creator unboxed a telehealth TRT package and made several specific claims worth examining. He identified testosterone cypionate at 200mg/mL, described enclomiphene as optional for fertility preservation and testicular size maintenance, and listed injection supplies. His headline claim: "I pay under $200 a month for absolutely everything" including telemedicine visits and quarterly bloodwork. He then solicited followers to comment "TRT" to receive clinic referral information.

This video is essentially a paid or affiliate promotion framed as an unboxing. That context matters when evaluating every claim he makes. The price point is real for some telehealth clinics, but the completeness and suitability of this specific package for any given viewer is a separate question entirely.

Does the science back this up?

The core clinical picture is reasonable. Testosterone cypionate is the most commonly prescribed form of injectable TRT in the US, and 200mg/mL is a standard concentration. The addition of enclomiphene as a co-treatment is a legitimate clinical strategy, though the evidence base is still developing.

Enclomiphene citrate (a selective estrogen receptor modulator) stimulates the hypothalamic-pituitary axis to maintain endogenous LH and FSH signaling, which does support intratesticular testosterone production and spermatogenesis. A 2019 randomized controlled trial by Kim et al. in the Journal of Urology found enclomiphene maintained sperm parameters better than testosterone replacement alone in hypogonadal men. So the fertility preservation claim has real support. The testicular atrophy claim is also biologically sound: exogenous testosterone suppresses LH, which reduces Leydig cell stimulation and intratesticular volume over time. Enclomiphene partially counters that suppression. That part checks out.

The price claim is harder to verify. Telehealth TRT costs vary widely, but platforms like Defy Medical, Maximus, and others do offer bundled packages in the $150-250/month range. Under $200 is plausible, not exceptional.

What did they get wrong (or right)?

He got the pharmacology mostly right. Testosterone cypionate, injection technique supplies (separate draw and inject needles is correct practice), and the role of enclomiphene are all described accurately enough for a layperson explainer.

What he got wrong, or at minimum dangerously incomplete, is the framing. He calls enclomiphene "end chlamofene" and describes it casually as optional, like an add-on feature. Enclomiphene is not FDA-approved for male hypogonadism. It's being used off-label, and that distinction matters legally and medically. He also provides zero context about who is or isn't a candidate for TRT, what low testosterone actually means clinically, or what side effects look like. The American Urological Association's 2018 guidelines specify that TRT should only be initiated in symptomatic patients with confirmed low testosterone on at least two morning measurements. None of that nuance appears here.

The referral solicitation at the end ("comment the word TRT") is a direct marketing tactic. Viewers should know they are being recruited to a clinic, not just educated.

What should you actually know?

If you are genuinely considering TRT, the process should start with proper diagnosis, not a TikTok unboxing. Symptoms alone are not enough. Two fasting morning testosterone measurements, along with LH, FSH, SHBG, and a full metabolic panel, are the baseline before any prescribing should happen. Morgentaler et al. (2016, Mayo Clinic Proceedings) reviewed the evidence base for TRT and emphasized that patient selection is the most important variable in outcomes.

TRT has real risks: erythrocytosis (elevated red blood cell count), cardiovascular considerations, and permanent suppression of natural testosterone production if used long-term without adjunct therapy. The FDA added a cardiovascular risk warning to all testosterone products in 2015 based on post-market surveillance data. A bundled $200 package does not make those risks disappear.

Quarterly bloodwork is the minimum, not a luxury. Hematocrit should be monitored every 3-6 months in the first year. If a clinic is not doing that, find a different clinic.

Is the referral at the end a red flag?

Yes, partially. Asking followers to comment a keyword to receive clinic information is a textbook affiliate or referral arrangement. That does not make the clinic bad, but it means the creator has a financial incentive to send you there. The information he's sharing is shaped by that relationship. FormBlends recommends verifying any telehealth TRT provider's credentials independently: check that prescribing physicians are licensed in your state, that the clinic requires baseline labs before prescribing, and that it follows established clinical guidelines rather than simply approving everyone who inquires.